US6710058B2
(en)
|
2000-11-06 |
2004-03-23 |
Bristol-Myers Squibb Pharma Company |
Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
|
US7030141B2
(en)
|
2001-11-29 |
2006-04-18 |
Christopher Franklin Bigge |
Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
|
PL213783B1
(en)
|
2002-03-13 |
2013-05-31 |
Janssen Pharmaceutica Nv |
Inhibitors of histone deacetylase
|
ES2306858T3
(en)
|
2002-03-13 |
2008-11-16 |
Janssen Pharmaceutica Nv |
CARBONILAMINE DERIVATIVES AS NEW INHIBITORS OF HISTONADESACETILASAS.
|
TW200307667A
(en)
*
|
2002-05-06 |
2003-12-16 |
Bristol Myers Squibb Co |
Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
|
WO2003099284A1
(en)
|
2002-05-22 |
2003-12-04 |
Amgen Inc. |
Amino-pyridine, -pyridine and pyridazine derivatives for use as vanilloid receptor ligands for the treatment of pain
|
ATE323702T1
(en)
|
2002-08-06 |
2006-05-15 |
Astrazeneca Ab |
CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY
|
NZ537952A
(en)
|
2002-08-08 |
2008-04-30 |
Amgen Inc |
Vanilloid receptor ligands and their use in treatments
|
EP1479674A1
(en)
*
|
2003-05-19 |
2004-11-24 |
Aventis Pharma Deutschland GmbH |
Imidiazole-derivatives as factor xa inhibitors
|
CA2507624A1
(en)
*
|
2002-12-04 |
2004-06-17 |
Aventis Pharma Deutschland Gmbh |
Imidazole-derivatives as factor xa inhibitors
|
US7358268B2
(en)
|
2002-12-04 |
2008-04-15 |
Sanofi-Aventis Deutschland Gmbh |
Imidazole derivatives as factor Xa inhibitors
|
UA80171C2
(en)
|
2002-12-19 |
2007-08-27 |
Pfizer Prod Inc |
Pyrrolopyrimidine derivatives
|
EP1479678A1
(en)
*
|
2003-05-19 |
2004-11-24 |
Aventis Pharma Deutschland GmbH |
Pyrazole-derivatives as factor xa inhibitors
|
US7429581B2
(en)
|
2002-12-23 |
2008-09-30 |
Sanofi-Aventis Deutschland Gmbh |
Pyrazole-derivatives as factor Xa inhibitors
|
AU2003292218A1
(en)
*
|
2002-12-23 |
2004-07-14 |
Sanofi-Aventis Deutschland Gmbh |
PYRAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS
|
US7696225B2
(en)
|
2003-01-06 |
2010-04-13 |
Osi Pharmaceuticals, Inc. |
(2-carboxamido)(3-Amino) thiophene compounds
|
TWI299664B
(en)
|
2003-01-06 |
2008-08-11 |
Osi Pharm Inc |
(2-carboxamido)(3-amino)thiophene compounds
|
US7317027B2
(en)
|
2003-05-19 |
2008-01-08 |
Sanofi-Aventis Deutschland Gmbh |
Azaindole-derivatives as factor Xa inhibitors
|
US7223780B2
(en)
|
2003-05-19 |
2007-05-29 |
Sanofi-Aventis Deutschland Gmbh |
Triazole-derivatives as blood clotting enzyme factor Xa inhibitors
|
EP1479679A1
(en)
*
|
2003-05-19 |
2004-11-24 |
Aventis Pharma Deutschland GmbH |
Triazole-derivatives as factor Xa inhibitors
|
EP1479680A1
(en)
*
|
2003-05-19 |
2004-11-24 |
Aventis Pharma Deutschland GmbH |
Azaindole derivatives as Factor Xa inhibitors
|
TWI372050B
(en)
|
2003-07-03 |
2012-09-11 |
Astex Therapeutics Ltd |
(morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
|
CA2532965C
(en)
|
2003-07-22 |
2013-05-14 |
Astex Therapeutics Limited |
3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators
|
SE0302573D0
(en)
|
2003-09-26 |
2003-09-26 |
Astrazeneca Ab |
Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
|
JP2007522233A
(en)
|
2004-02-11 |
2007-08-09 |
アムジエン・インコーポレーテツド |
Vanilloid receptor ligands and their use in therapy
|
MY139645A
(en)
|
2004-02-11 |
2009-10-30 |
Amgen Inc |
Vanilloid receptor ligands and their use in treatments
|
EP1568698A1
(en)
*
|
2004-02-27 |
2005-08-31 |
Aventis Pharma Deutschland GmbH |
Pyrrole-derivatives as factor Xa inhibitors
|
KR101197482B1
(en)
|
2004-03-05 |
2012-11-09 |
닛산 가가쿠 고교 가부시키 가이샤 |
Isoxazoline-Substituted Benzamide Compound And Noxious Organism Control Agent
|
US8710232B2
(en)
|
2004-04-22 |
2014-04-29 |
Sanofi-Aventis Deutschland Gmbh |
Imidazole derivatives used as TAFIa inhibitors
|
US7696352B2
(en)
|
2004-06-18 |
2010-04-13 |
Millennium Pharmaceuticals, Inc. |
Factor Xa inhibitors
|
EP1893572B1
(en)
|
2004-06-18 |
2016-12-14 |
Millennium Pharmaceuticals, Inc. |
Factor xa inhibitors
|
SE0401653D0
(en)
*
|
2004-06-24 |
2004-06-24 |
Astrazeneca Ab |
New compounds
|
US7772271B2
(en)
|
2004-07-14 |
2010-08-10 |
Ptc Therapeutics, Inc. |
Methods for treating hepatitis C
|
US7868037B2
(en)
|
2004-07-14 |
2011-01-11 |
Ptc Therapeutics, Inc. |
Methods for treating hepatitis C
|
US7781478B2
(en)
|
2004-07-14 |
2010-08-24 |
Ptc Therapeutics, Inc. |
Methods for treating hepatitis C
|
BRPI0511834A
(en)
|
2004-07-14 |
2008-01-08 |
Ptc Therapeutics Inc |
methods for treating hepatitis c
|
NZ553329A
(en)
|
2004-07-22 |
2010-09-30 |
Ptc Therapeutics Inc |
Thienopyridines for treating hepatitis C
|
NZ552865A
(en)
|
2004-07-28 |
2009-09-25 |
Janssen Pharmaceutica Nv |
Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
|
MX2007000791A
(en)
|
2004-08-03 |
2007-03-23 |
Wyeth Corp |
Indazoles useful in treating cardiovascular diseases.
|
KR101269869B1
(en)
|
2004-09-24 |
2013-06-07 |
네오메드 인스티튜트 |
Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
|
CA2587678C
(en)
|
2004-11-16 |
2013-05-21 |
Janssen Pharmaceutica N.V. |
Novel heterocycle derivatives useful as selective androgen receptor modulators (sarms)
|
DE102004058062A1
(en)
*
|
2004-12-02 |
2006-06-08 |
Bayer Healthcare Ag |
Cyclic iminocarbamates and their use
|
DE602005009252D1
(en)
|
2004-12-08 |
2008-10-02 |
Bristol Myers Squibb Co |
Heterocyclic Compounds as Inhibitors of Factor VIIA
|
DE102004059219A1
(en)
*
|
2004-12-09 |
2006-06-14 |
Bayer Healthcare Ag |
Pyrazine dicarboxylic acid amides and their use
|
DE102004061747A1
(en)
*
|
2004-12-22 |
2006-07-06 |
Bayer Healthcare Ag |
Thiophene-substituted pyrazolines
|
DE102004061751A1
(en)
*
|
2004-12-22 |
2006-07-06 |
Bayer Healthcare Ag |
Cyanoguanidine-substituted pyrazolines
|
TWI427077B
(en)
|
2004-12-30 |
2014-02-21 |
Astex Therapeutics Ltd |
Pyrazole compound and use thereof and pharmaceutical composition containing the same
|
US20090036435A1
(en)
|
2005-01-21 |
2009-02-05 |
Astex Therapeutics Limited |
Pharmaceutical Compounds
|
AU2006207321B2
(en)
|
2005-01-21 |
2012-09-06 |
Astex Therapeutics Limited |
Pharmaceutical compounds
|
AR054425A1
(en)
|
2005-01-21 |
2007-06-27 |
Astex Therapeutics Ltd |
PIPERIDIN ADDITION SALTS 4-IL-ACID AMID 4- (2,6-DICLORO-BENZOILAMINO) 1H-PIRAZOL-3-CARBOXILICO.
|
US8404718B2
(en)
|
2005-01-21 |
2013-03-26 |
Astex Therapeutics Limited |
Combinations of pyrazole kinase inhibitors
|
WO2006089311A1
(en)
|
2005-02-15 |
2006-08-24 |
Amgen Inc. |
Vanilloid receptor ligands and their use in treatments
|
BRPI0607688A2
(en)
|
2005-02-17 |
2009-09-22 |
Synta Pharmaceuticals Corp |
method for inhibiting tubulin polymerization in a cell; method for treating or preventing a proliferative disorder in an individual; method of blocking, occluding or otherwise disrupting blood flow to the neovasculature; compound; pharmaceutical composition and use of said method and compound
|
EP1757290A1
(en)
|
2005-08-16 |
2007-02-28 |
Zentaris GmbH |
Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors
|
DE102005042583A1
(en)
*
|
2005-09-08 |
2007-03-15 |
Bayer Healthcare Ag |
Iminooxazolidine derivatives and their use
|
TWI385169B
(en)
|
2005-10-31 |
2013-02-11 |
Eisai R&D Man Co Ltd |
Heterocyclic substituted pyridine derivatives and antifungal agent containing same
|
AU2006327317B2
(en)
|
2005-12-23 |
2010-11-25 |
Astrazeneca Ab |
GABA-B receptor modulators
|
BRPI0620345A2
(en)
*
|
2005-12-23 |
2017-11-21 |
Astrazeneca Ab |
compound, pharmaceutical composition, use of a compound, and method for treating a disease
|
CN101341130A
(en)
|
2005-12-23 |
2009-01-07 |
阿斯利康(瑞典)有限公司 |
Imidazole derivatives for the treatment of gastrointestinal disorders
|
ES2684821T3
(en)
|
2005-12-29 |
2018-10-04 |
Lexicon Pharmaceuticals, Inc. |
Multicyclic amino acid derivatives and methods of their use
|
EP1968579A1
(en)
|
2005-12-30 |
2008-09-17 |
Astex Therapeutics Limited |
Pharmaceutical compounds
|
CA2630717C
(en)
|
2006-01-19 |
2015-02-24 |
Janssen Pharmaceutica N.V. |
Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
|
US8198466B2
(en)
|
2006-02-03 |
2012-06-12 |
Bionomics Limited |
Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors
|
TW200745049A
(en)
|
2006-03-23 |
2007-12-16 |
Astrazeneca Ab |
New crystalline forms
|
TW200808769A
(en)
|
2006-04-18 |
2008-02-16 |
Astrazeneca Ab |
Therapeutic compounds
|
TW200813017A
(en)
|
2006-05-05 |
2008-03-16 |
Millennium Pharm Inc |
Factor XA inhibitors
|
WO2008001115A2
(en)
|
2006-06-29 |
2008-01-03 |
Astex Therapeutics Limited |
Pharmaceutical combinations of 1-cyclopropyl-3- [3- (5-m0rphoolin-4-ylmethyl-1h-benzoimidazol-2-yl) -lh-1-pyrazol- 4-yl] -urea
|
ES2528797T3
(en)
|
2006-08-21 |
2015-02-12 |
Genentech, Inc. |
Aza-benzothiophenyl compounds and methods of use
|
US7964732B2
(en)
|
2006-11-17 |
2011-06-21 |
Pfizer Inc. |
Substituted bicyclocarboxyamide compounds
|
UA99270C2
(en)
|
2006-12-12 |
2012-08-10 |
Лексикон Фармасьютикалз, Инк. |
4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
|
AR067336A1
(en)
|
2007-06-28 |
2009-10-07 |
Novartis Ag |
CALICREIN MODULATORS 7
|
NZ585298A
(en)
|
2007-11-16 |
2012-08-31 |
Rigel Pharmaceuticals Inc |
Carboxamide, sulfonamide and amine compounds for metabolic disorders
|
JP5650540B2
(en)
|
2007-12-12 |
2015-01-07 |
ライジェル ファーマシューティカルズ, インコーポレイテッド |
Carboxamide, sulfonamide, and amine compounds for metabolic disorders
|
US8513287B2
(en)
|
2007-12-27 |
2013-08-20 |
Eisai R&D Management Co., Ltd. |
Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
|
ES2552549T3
(en)
|
2008-04-23 |
2015-11-30 |
Rigel Pharmaceuticals, Inc. |
Carboxamide compounds for the treatment of metabolic disorders
|
AR072297A1
(en)
|
2008-06-27 |
2010-08-18 |
Novartis Ag |
DERIVATIVES OF INDOL-2-IL-PIRIDIN-3-ILO, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND ITS USE IN MEDICINES FOR THE TREATMENT OF DISEASES MEDIATED BY THE SYNTHESIS ALDOSTERONE.
|
EP2303841A1
(en)
|
2008-07-14 |
2011-04-06 |
Gilead Sciences, Inc. |
Oxindolyl inhibitor compounds
|
AU2009271019A1
(en)
|
2008-07-14 |
2010-01-21 |
Gilead Sciences, Inc. |
Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases
|
AU2009271003A1
(en)
|
2008-07-14 |
2010-01-21 |
Gilead Sciences, Inc. |
Imidazolylpyrimidine compounds as HDAC and/or CDK inhibitors
|
MX2011001090A
(en)
|
2008-07-28 |
2011-03-15 |
Gilead Sciences Inc |
Cycloalkylidene and heterocycloalkylidene histone deacetylase inhibitor compounds.
|
US8455499B2
(en)
|
2008-12-11 |
2013-06-04 |
Amira Pharmaceuticals, Inc. |
Alkyne antagonists of lysophosphatidic acid receptors
|
GB2466121B
(en)
|
2008-12-15 |
2010-12-08 |
Amira Pharmaceuticals Inc |
Antagonists of lysophosphatidic acid receptors
|
US8765735B2
(en)
|
2009-05-18 |
2014-07-01 |
Infinity Pharmaceuticals, Inc. |
Isoxazolines as inhibitors of fatty acid amide hydrolase
|
US9149465B2
(en)
|
2009-05-18 |
2015-10-06 |
Infinity Pharmaceuticals, Inc. |
Isoxazolines as inhibitors of fatty acid amide hydrolase
|
US8927551B2
(en)
|
2009-05-18 |
2015-01-06 |
Infinity Pharmaceuticals, Inc. |
Isoxazolines as inhibitors of fatty acid amide hydrolase
|
GB2470833B
(en)
|
2009-06-03 |
2011-06-01 |
Amira Pharmaceuticals Inc |
Polycyclic antagonists of lysophosphatidic acid receptors
|
AU2010256360A1
(en)
|
2009-06-05 |
2012-01-12 |
Astrazeneca Ab |
Aminopyrrolidinone derivatives and uses thereof
|
BRPI1010884A2
(en)
|
2009-06-08 |
2016-03-15 |
Gilead Sciences Inc |
hdac alkanoylamino benzamide aniline inhibitors compound
|
US8283357B2
(en)
|
2009-06-08 |
2012-10-09 |
Gilead Sciences, Inc. |
Cycloalkylcarbamate benzamide aniline HDAC inhibitor compounds
|
EP2462128B1
(en)
|
2009-08-04 |
2016-09-21 |
Amira Pharmaceuticals, Inc. |
Compounds as lysophosphatidic acid receptor antagonists
|
GB2474748B
(en)
|
2009-10-01 |
2011-10-12 |
Amira Pharmaceuticals Inc |
Polycyclic compounds as lysophosphatidic acid receptor antagonists
|
GB2474120B
(en)
|
2009-10-01 |
2011-12-21 |
Amira Pharmaceuticals Inc |
Compounds as Lysophosphatidic acid receptor antagonists
|
EP2513094B1
(en)
|
2009-12-17 |
2015-12-16 |
Millennium Pharmaceuticals, Inc. |
Crystalline salts of a factor xa inhibitor
|
US8742120B2
(en)
|
2009-12-17 |
2014-06-03 |
Millennium Pharmaceuticals, Inc. |
Methods of preparing factor xa inhibitors and salts thereof
|
KR101955691B1
(en)
|
2010-03-30 |
2019-03-07 |
베르선 코포레이션 |
Multisubstituted aromatic compounds as inhibitors of thrombin
|
US9290485B2
(en)
|
2010-08-04 |
2016-03-22 |
Novartis Ag |
N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
|
EP2431035A1
(en)
|
2010-09-16 |
2012-03-21 |
Æterna Zentaris GmbH |
Novel Triazole Derivatives with Improved Receptor Activity and Bioavailability Properties as Ghrelin Antagonists of Growth Hormone Secretagogue Receptors
|
SG189420A1
(en)
|
2010-11-11 |
2013-05-31 |
Sanofi Sa |
Process for the preparation of 3-(6-amino-pyridin-3yl)-2-acrylic acid derivatives
|
EP2694496A1
(en)
|
2011-04-05 |
2014-02-12 |
Amira Pharmaceuticals, Inc. |
3- or 5 - bi phenyl - 4 - ylisoxazole - based compounds useful for the treatment of fibrosis, pain, cancer and respiratory, allergic, nervous system or cardiovascular disorders
|
EP2744807A4
(en)
|
2011-08-15 |
2015-03-04 |
Intermune Inc |
Lysophosphatidic acid receptor antagonists
|
EP2755652B1
(en)
|
2011-09-16 |
2021-06-02 |
Novartis AG |
N-substituted heterocyclyl carboxamides
|
US9199975B2
(en)
|
2011-09-30 |
2015-12-01 |
Asana Biosciences, Llc |
Biaryl imidazole derivatives for regulating CYP17
|
KR101093102B1
(en)
|
2011-10-04 |
2011-12-13 |
(주)목우연구소 |
Phenylisoxazoline compound having herbicidal activity and uses thereof
|
AU2013225938B2
(en)
|
2012-02-29 |
2017-08-10 |
Chemocentryx, Inc. |
Pyrazol-1-yl benzene sulfonamides as CCR9 antagonists
|
CA2891412A1
(en)
|
2012-11-20 |
2014-05-30 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of indoleamine 2,3-dioxygenase
|
TW201444798A
(en)
|
2013-02-28 |
2014-12-01 |
必治妥美雅史谷比公司 |
Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors
|
WO2014134391A1
(en)
|
2013-02-28 |
2014-09-04 |
Bristol-Myers Squibb Company |
Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors
|
EP2968275B1
(en)
|
2013-03-15 |
2017-11-29 |
Bristol-Myers Squibb Company |
Lxr modulators
|
CN105209440B
(en)
|
2013-03-15 |
2019-07-23 |
维颂公司 |
Halo-pyrazole as thrombin inhibitor
|
RU2019101889A
(en)
|
2013-03-15 |
2019-03-28 |
Версеон Корпорейшн |
POLYSEMBATED AROMATIC COMPOUNDS AS SERINE PROTEASES INHIBITORS
|
CN106163527A
(en)
|
2013-11-22 |
2016-11-23 |
Cl生物科技有限责任公司 |
For treating and preventing the gastrin antagonists of osteoporosis
|
WO2015089800A1
(en)
|
2013-12-19 |
2015-06-25 |
Eli Lilly And Company |
Fluorophenyl pyrazol compounds
|
PL3113772T3
(en)
*
|
2014-03-07 |
2021-04-06 |
Biocryst Pharmaceuticals, Inc. |
Trifluoromethyl substituted pyrazoles as human plasma kallikrein inhibitors
|
CA2942387A1
(en)
|
2014-03-13 |
2015-09-17 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions and methods of increasing cftr actvity
|
WO2015138909A1
(en)
|
2014-03-13 |
2015-09-17 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions, and methods for increasing cftr activity
|
PT3152199T
(en)
|
2014-06-03 |
2018-11-26 |
Idorsia Pharmaceuticals Ltd |
Pyrazole compounds and their use as t-type calcium channel blockers
|
CA2952862A1
(en)
|
2014-06-19 |
2015-12-23 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions and methods of increasing cftr activity
|
CN107074822B
(en)
|
2014-09-15 |
2020-01-03 |
爱杜西亚药品有限公司 |
Triazole compounds as T-type calcium channel blockers
|
CA2960790A1
(en)
|
2014-09-17 |
2016-03-24 |
Verseon Corporation |
Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
|
NZ768528A
(en)
|
2014-10-06 |
2024-03-22 |
Chemocentryx Inc |
Combination therapy of inhibitors of c-c chemokine receptor type 9 (ccr9) and anti-α4β7 integrin blocking antibodies
|
CA2971855A1
(en)
|
2014-12-23 |
2016-06-30 |
Proteostasis Therapeutics, Inc. |
Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis
|
US10344023B2
(en)
|
2014-12-23 |
2019-07-09 |
Proteostasis Therapeutics, Inc. |
Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis
|
MA41253A
(en)
|
2014-12-23 |
2017-10-31 |
Proteostasis Therapeutics Inc |
COMPOUNDS, COMPOSITIONS AND PROCESSES TO INCREASE THE ACTIVITY OF CFTR
|
US10392378B2
(en)
|
2014-12-23 |
2019-08-27 |
Proteostasis Therapeutics, Inc. |
Derivatives of 5-phenyl- or 5-heteroarylathiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis
|
US10532995B2
(en)
|
2015-02-27 |
2020-01-14 |
Verseon Corporation |
Substituted pyrazole compounds as serine protease inhibitors
|
WO2016208602A1
(en)
|
2015-06-23 |
2016-12-29 |
キッセイ薬品工業株式会社 |
Pyrazole derivative, or pharmaceutically acceptable salt thereof
|
AU2016297886B2
(en)
|
2015-07-24 |
2020-12-10 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions and methods of increasing CFTR activity
|
EP4086249A3
(en)
|
2015-09-02 |
2023-02-15 |
Trevena, Inc. |
6-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
|
JP6929276B2
(en)
|
2015-10-06 |
2021-09-01 |
プロテオステイシス セラピューティクス,インコーポレイテッド |
Compounds, pharmaceutically acceptable salts or stereoisomers thereof and pharmaceutical compositions
|
KR102448404B1
(en)
|
2016-04-07 |
2022-09-27 |
프로테오스타시스 테라퓨틱스, 인크. |
Silicon atom-containing ivacarpter analogues
|
US10899751B2
(en)
|
2016-06-21 |
2021-01-26 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions, and methods for increasing CFTR activity
|
TW201825465A
(en)
|
2016-09-23 |
2018-07-16 |
美商基利科學股份有限公司 |
Phosphatidylinositol 3-kinase inhibitors
|
TW201815787A
(en)
|
2016-09-23 |
2018-05-01 |
美商基利科學股份有限公司 |
Phosphatidylinositol 3-kinase inhibitors
|
TW201813963A
(en)
|
2016-09-23 |
2018-04-16 |
美商基利科學股份有限公司 |
Phosphatidylinositol 3-kinase inhibitors
|
PT3554490T
(en)
|
2016-12-16 |
2022-03-17 |
Idorsia Pharmaceuticals Ltd |
Pharmaceutical combination comprising a t-type calcium channel blocker
|
CA3050348A1
(en)
|
2017-02-06 |
2018-08-09 |
Idorsia Pharmaceuticals Ltd |
A novel process for the synthesis of 1-aryl-1-trifluoromethylcyclopropanes
|
CN110446495B
(en)
|
2017-02-17 |
2023-09-05 |
特维娜有限公司 |
Delta opioid receptor modulating compounds containing 7-membered aza heterocycles and methods of use and preparation thereof
|
KR20190129867A
(en)
|
2017-02-17 |
2019-11-20 |
트레베나, 인코포레이티드. |
5-membered aza-heterocycle-containing delta-opioid receptor modulating compounds, and methods of using and preparing the same
|
JP2020528412A
(en)
|
2017-07-21 |
2020-09-24 |
アンタビオ エスアーエス |
Chemical compound
|
KR20200143376A
(en)
|
2018-03-13 |
2020-12-23 |
샤이어 휴먼 지네틱 테라피즈 인크. |
Substituted imidazopyridines and uses thereof as plasma kallikrein inhibitors
|
EP3587416A1
(en)
|
2018-06-29 |
2020-01-01 |
Institut Univ. de Ciència i Tecnologia, S.A. |
2-oxopiperidin-3-yl derivatives and use thereof
|
JP7337174B2
(en)
|
2018-09-18 |
2023-09-01 |
ニカング セラピューティクス, インコーポレイテッド |
Trisubstituted Heteroaryl Derivatives as Src Homology-2 Phosphatase Inhibitors
|
WO2020113094A1
(en)
|
2018-11-30 |
2020-06-04 |
Nuvation Bio Inc. |
Pyrrole and pyrazole compounds and methods of use thereof
|
KR102135106B1
(en)
*
|
2018-12-11 |
2020-07-17 |
재단법인 경기도경제과학진흥원 |
Antiviral Composition for Middle East Respiratory Syndrome Coronavirus
|
JP2022548696A
(en)
|
2019-09-18 |
2022-11-21 |
武田薬品工業株式会社 |
Plasma kallikrein inhibitors and uses thereof
|
US11370803B2
(en)
|
2019-09-18 |
2022-06-28 |
Takeda Pharmaceutical Company Limited |
Heteroaryl plasma kallikrein inhibitors
|
US10792360B1
(en)
|
2019-11-21 |
2020-10-06 |
Chemocentryx, Inc. |
Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies
|
US11091447B2
(en)
|
2020-01-03 |
2021-08-17 |
Berg Llc |
UBE2K modulators and methods for their use
|
IL309232A
(en)
|
2021-06-14 |
2024-02-01 |
Scorpion Therapeutics Inc |
Urea derivatives which can be used to treat cancer
|
EP4356909A1
(en)
|
2022-10-17 |
2024-04-24 |
Selabtec Sciences, SLU |
1-(sulfonyl)-n-phenylpyrrolidine-2-carboxamides derivatives and use thereof
|